← SynDRA
UPADACITINIB
SynDRA canonical compound SYN0038347 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | JAK1 |
|---|
| Mechanism of action | JAK inhibitor |
|---|
All known targets
- JAK1
- JAK2
- JAK3
- TYK2
- AAK1
- GAK
Mechanisms of action (all sources)
- TYK2 INHIBITOR
- Tyrosine-protein kinase TYK2 inhibitor
- JAK3 INHIBITOR
- Tyrosine-protein kinase JAK3 inhibitor
- JAK2 INHIBITOR
- Tyrosine-protein kinase JAK2 inhibitor
- JAK1 INHIBITOR
- Tyrosine-protein kinase JAK1 inhibitor
- JAK inhibitor
- JAK1 MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- RET
- TNK2
- STK16
- PRKCQ
- ROCK2
- ROCK1
- FGFR1
- LTK
- CAMK1D
- PRKAA1
- LCK
- GRK5
- AURKB
- AURKA
- ALK
- KDR
- RPS6KA3
- PIM1
- PLK3
- PIM2
- PDGFRB
- PDGFRA
- PAK4
- OGG1
- NTRK3
- NTRK2
- NTRK1
- PRKACA
- ABL1
- PRKCZ
- SYK
- UNG
- TYRO3
- TTK
- TDG
- TBK1
- TAOK2
- STK33
- PRKD3
- SRC
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Antirheumatic Agents
- Enzyme Inhibitors
- Janus Kinase Inhibitors
- Protein Kinase Inhibitors
- Janus Kinase Inhibitor
ATC classes
- L04A · IMMUNOSUPPRESSANTS
Cross-references
Synonyms
- RINVOQ
- RINVOQ LQ
- Rinvoq
- upadacitinib hydrate
- ABT-494
- rinvoq
- Upadacitinib anhydrous
- Upadacitinib component of abbv-599
- 4RA0KN46E0
- ABT 494
- ABBV-599 COMPONENT UPADACITINIB
- upadacitinibum
- RefChem:57163
- L04AA44
- DTXCID401513480
- UNII-4RA0KN46E0
- C17H19F3N6O
- Upadacitinib [USAN]
- Upadacitinib (Standard)
- UPADACITINIB [MI]
- Upadacitinib, ABT-494
- Upadacitinib (USAN/INN)
- UPADACITINIB [INN]
- Upadacitinib [USAN:INN]
- Upadacitinib (ABT-494)
- UPADACITINIB [WHO-DD]
- GTPL9246
- orb1299762
- SCHEMBL9991056
- WYQFJHHDOKWSHR-MNOVXSKESA-N
- GLXC-10425
- UPADACITINIB [ORANGE BOOK]
- EX-A1628
- BDBM50503287
- EBC-26865
- HY-19569R
- s8162
- AKOS030567686
Look up UPADACITINIB in the interactive SynDRA portal →